secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2024-11-27T23:59:59+00:00
Accession:  0001493152-24-048065
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Vivos stockholders elect all director nominees and approve 2024 equity plan at annual meeting
--------------------------------------------------------------------------------

- Six directors elected: Huntsman, Green, Krammer, Lindsay, Sokolow, Thompson; each received ~1.1M for, ~155-193K withheld.
- 2024 Omnibus Equity Incentive Plan approved with 957,268 for, 313,560 against, 17,747 abstentions.
- Ratification of Moss Adams LLP as auditor for FY2024 passed with 2,496,723 for, 162,219 against, 35,623 abstentions.
- Approximately 2.7M of 4.8M outstanding shares voted, constituting a quorum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224048065/0001493152-24-048065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224048065/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-048065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer